John W. Beck, CPA is currently Chief Executive Officer of Wellspring Water Technologies and also Chief Executive Officer of West Tech Medical, LLC, companies he co-founded. Previously, he served as Chief Financial Officer and Senior Vice President of Finance & Operations of Ardea Biosciences Inc., from 2008 until the acquisition by AstraZeneca in 2012 for $1.26B. He co-founded Metabasis Therapeutics Inc. in 1999 and served as its Chief Financial Officer from 2005 until 2008. In February 1994 he joined Neurocrine Biosciences, Inc., where he served as Director of Finance from May 1996 to April 1998 and played an important role in Neurocrine’s 1996 initial public offering. Mr. Beck received a B.A. in Accounting from the University of Washington and also holds a Th.B. in theology from a Seattle, Washington-based seminary.
Mike is an accomplished leader with over 20 years of broad experience in biopharma drug, medical device and healthcare development and corporate management. He has extensive strategic, financial and operational expertise, with experience in business financial operations, investor and media relations, portfolio planning, project and alliance management, protein biochemistry and process development. Most recently, Mike was CEO and President of NanoScopia, Inc., a medical device research and development company. Mike worked for nearly 20 years at ZymoGenetics, a Seattle-based biotech company and subsidiary of Bristol Myers-Squibb. Mike held positions of increasing responsibility in several departments during his tenure at ZymoGenetics, culminating in his role as Site Lead & Director of Operations. Mike holds a Bachelors of Business Administration in Finance from the University of Notre Dame and a Bachelors of Science in Genetics and Cell Biology from the University of Minnesota.
Miguel de los Rios, PhD
Miguel de los Rios is a passionate entrepreneur focused on building and developing novel therapeutics to satisfy unmet needs in human medicine. He received his Ph.D. In biophysical chemistry and a BS in cell biology, both at UCSB. Currently, Miguel is Founding CEO of Rift Biotherapeutics, a therapeutic antibody company focused on modulating novel mechanisms to ignite the immune system against cancers. Miguel also serves as Vice President of Research and Development at Sevion Therapeutics (formerly Fabrus, Inc.), a clinical stage therapeutics company with a focus in oncology and autoimmune disorders. Previously, he founded Chimeros, Inc., a venture-backed biologics therapeutic company in 2003 while working to complete his Ph.D. at UCSB. At Chimeros, he served as both the Chief Executive Officer as well as the Chief Scientific Officer from 2003-2011, and was the inventor of the company’s core technologies. He continues to build and help launch companies whose missions are to radically disrupt current medical approaches. Miguel is a council member of the University of California Innovations Council where he works the entire UC system to aid system-wide innovation. He also advises several start-up biotechnology companies and venture capital firms. Miguel is lead author or inventor on 50 publications, patents and patent applications. He is also the founding blacksmith at Angel’s Forge.